FDA INDICATIONS AND USAGE¹
- Cambia is a non-steroidal anti-inflammatory drug used to treat acute migraine attacks in adults 18 years of age and older.

APPROVAL CRITERIA¹,²
1. The patient has the diagnosis of migraine headaches with or without aura AND;
2. The patient is at least 18 years of age or older AND;
3. The patient has tried and failed at least two other NSAIDS, including diclofenac potassium tablets. If unable to swallow tablets at least one liquid NSAID must have been trialed AND;
4. The patient has tried and failed at least two triptans or has a contraindication to their use AND;
5. Cambia is not being used every day.

DENIAL CRITERIA
1. Patient does not have migraine diagnosis OR;
2. Has a known hypersensitivity to diclofenac or any of its excipients or other NSAIDS OR;
3. Age < 18 years.
4. The patient has not tried and failed at least two other NSAIDS, including diclofenac potassium tablets OR;
5. The patient has not tried and failed at least two triptans, with the exception of a contraindication OR;
6. Cambia is being used every day.

CAUTIONS¹
- NSAIDS can cause an increased risk for cardiovascular events.
- NSAIDS can cause an increased risk for gastrointestinal adverse events.

DURATION OF APPROVAL
- Initial Approval: up to 6 months
  - Reauthorization Approval: up to 12 months

QUANTITY LIMIT
- 9 – 50mg Cambia packets per month
REFERENCES / FOOTNOTES:
